New Lipitor ad features testimonial from heart attack survivor

Share this article:
Lipitor ad
Lipitor ad

Pfizer will resume DTC advertising for its blockbuster statin drug, Lipitor (atorvastatin calcium)--but this time the pitchman isn't so famous. Pfizer took heat from federal regulators and the media when it used artificial heart inventor Robert Jarvik (not a physician) to promote Lipitor for its previous Lipitor DTC campaign. This time around Pfizer is using a “real person” who suffered a heart attack.

In the new print and television advertisements, which were set to appear the first week of September, the patient tells viewers and readers: “Talk about a wake-up call. I had a heart attack at 57. I should have been doing more for my high cholesterol. I learned the hard way.” The copy goes on to say: “Now I trust my heart to Lipitor. Talk to your doctor about your risk and about Lipitor.” The main theme of the new ad campaign is “a Lipitor heart-to-heart.”

Separately, Pfizer unveiled data from a five-year Treating to New Targets (TNT) study presented at the 2008 European Society of Cardiology Congress, that revealed in patients with established heart disease, Lipitor 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19% compared to Lipitor 10 mg, but also provided a sustained reduction in the risk of a subsequent second, third, fourth and fifth cardiovascular event.

Lipitor, which had sales of $12.7 billion in 2007, will be facing stiff competition from generic versions of the drug when it looses its copyright protection in 2011.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.